The development of molecular genetics also provides new prognostic markers for AML, such as NPM1 mutation without FLT3-ITD and double CEBPA mutations are proved to be good prognostic indicators, while FLT3-ITD, ASXL1, RUNX1 and TP53 mutations are poor prognostic factors (2). Here, TP53 is linked to acute myeloid leukemia.